Approaches to M&As in pharma points to each company’s philosophy
Deal or no deal
Related Posts
NeuroSense Therapeutics shares positive results of lead candidate in ALS
The neurodegenerative disease currently affects more than 200,000 people worldwide NeuroSense Therapeutics has announced positive mid-stage results of its lead drug candidate, PrimeC, in people […]
IHI’s new funding round to include topics on CVD and arthritis
The initiative’s proposals aim to tackle current challenges in health research and innovation The Innovative Health Initiative (IHI) has launched a new call for proposals, […]
Cambridge researchers begin new trial for oesophageal cancer screening
If successful, the new test could see routine screening introduced in the NHS Researchers at Cambridge University Hospitals NHS Foundation Trust and the University of […]